Boundless Bio (BOLD) Financials

Boundless Bio (NASDAQ:BOLD) remains a pre-revenue biotechnology company with persistent operating losses and cash burn. The financial statements show substantial investment in research and development, but no reported revenue through the second quarter of 2026. Liquidity remains meaningful, although the company’s liquid-asset balance has declined considerably over the past two years.

• Solid liquidity remains available. As of June 30, 2026, Boundless Bio reported $20.2 million in cash and equivalents plus $52.4 million in short-term investments, for total liquid assets of approximately $72.6 million.
• Limited traditional debt burden. The latest balance sheet reported $7.8 million in total liabilities and no noncurrent liabilities, leaving shareholders’ equity at $66.0 million. This provides a stronger capital structure than many early-stage biotechnology companies that rely heavily on debt.
• Investment maturities have helped support cash levels. The company generated $31.5 million from sales or maturities of investments in Q2 2026, more than offsetting $8.4 million of investment purchases and producing $23.1 million of net investing cash flow.
• Recent equity issuance has been limited. Financing cash flow was only $73,000 in Q2 2026, compared with $0 in Q1 2026. This suggests the company was not relying on a major equity raise during the latest reporting period, limiting near-term dilution from reported financing activity.
• Research spending remains a significant strategic investment. Research and development expense rose to $14.0 million in Q2 2026 from $9.7 million in Q1 and $12.2 million in Q2 2025. Higher research spending could support future clinical progress, but it has not yet translated into revenue or profitability.
• Interest income provides a modest offset to operating losses. Interest and investment income was $690,000 in Q2 2026, down from $920,000 in Q1 2026 and $1.4 million in Q2 2025 as the company’s investment balances declined.
• Revenue remains at zero. Boundless Bio reported no revenue, cost of revenue or gross profit in the available income statements. The company therefore remains dependent on its cash and investment portfolio, potential financing, and future product development success.
• Net losses have worsened sharply in the latest quarter. Q2 2026 net loss was $23.7 million, or $1.06 per share, compared with a $13.6 million loss, or $0.60 per share, in Q1 2026. The latest loss was also substantially larger than the $15.7 million loss reported in Q2 2025.
• Operating expenses are accelerating. Total operating expenses increased to $24.4 million in Q2 2026 from $14.5 million in Q1 and $17.1 million in Q2 2025. Selling, general and administrative expense more than doubled year over year to $10.4 million, while R&D expense increased approximately 14%.
• Operating cash burn is increasing and reducing liquidity. Net cash used in operating activities rose to $21.0 million in Q2 2026 from $15.0 million in Q1 and $11.8 million in Q2 2025. Cash and short-term investments declined from $167.1 million in Q2 2024 to $118.3 million in Q2 2025 and $72.6 million in Q2 2026. At the latest quarterly operating burn rate, the current liquid-asset balance represents roughly three to four quarters of coverage, before changes in spending, investment maturities or new financing.

Overall, Boundless Bio’s balance sheet still offers near-term financial flexibility, but the trend is unfavorable for investors focused on operating performance. The company has no revenue, losses are widening, and cash consumption is increasing. Future valuation will likely depend heavily on clinical and development progress, along with the company’s ability to control spending or raise additional capital before its liquid resources become constrained.